Calidi Biotherapeutics Inc. CLDI Archives

TuesdayApr 29, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…

TuesdayApr 22, 2025 9:30 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline

Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including the FDA-cleared CLD-201, which is advancing toward trials for solid tumors. Additional program updates will include CLD-400 for metastatic and lung cancer and CLD-101 for high-grade gliomas. A live Q&A will follow the presentation. To view the full press release, visit: https://ibn.fm/WPzHW About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to…

ThursdayApr 17, 2025 9:25 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors

Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201, an allogeneic stem cell-based virotherapy targeting solid tumors including breast cancer, head and neck cancer, and soft tissue sarcoma. Backed by preclinical data showing immune system evasion and potent tumor-killing ability, CLD-201 is now cleared to enter clinical development. The therapy combines adipose-derived stem cells with oncolytic vaccinia virus, representing a novel immunotherapeutic approach for hard-to-treat cancers. To view the full press release, visit: https://ibn.fm/362xV About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s…

ThursdayApr 10, 2025 9:10 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer

Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a recently filed Investigational New Drug application. Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership roles at Parthenon Therapeutics and service as a surgical oncologist in the U.S. Army. His extensive experience in immunotherapy is expected to bolster Calidi’s efforts in developing stem cell-based and enveloped virus cancer therapies. To view the full press release, visit: https://ibn.fm/EJaAq About Calidi Biotherapeutics…

TuesdayApr 01, 2025 9:40 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi’s clinical and preclinical cancer therapy programs. To view the full press release, visit: https://ibn.fm/vL35L About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem…

FridayMar 21, 2025 2:28 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

FridayMar 14, 2025 3:35 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune response. Calidi’s pipeline includes three key therapies — RTNova, SuperNova and NeuroNova — that incorporate advanced technologies such as stem cells and antitumor viruses to target and destroy cancer cells. Calidi Biotherapeutics’ innovative therapies hold the potential to revolutionize cancer treatment by enhancing efficacy and stimulating…

WednesdayMar 05, 2025 2:39 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent article. “Calidi’s pipeline includes the proprietary SuperNova (‘SNV’) platform, which utilizes allogeneic adipose-derived mesenchymal stem cells (‘AD-MSCs’) as carriers for antitumor virotherapy. This approach has shown promise in preclinical studies and safety studies, with potential applications…

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi's RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi's groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect…

FridayFeb 28, 2025 10:45 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show

Calidi Biotherapeutics (NYSE American: CLDI) and OS Therapies Inc. (NYSE American: OSTX) will be featured on RedChip’s Small Stocks, Big Money™ show, airing on Bloomberg TV this Saturday, March 1, at 7 p.m. ET. Andrew Jackson, CFO of Calidi, will discuss the company’s stem cell-based oncolytic virotherapy platform designed to enhance cancer treatment. Calidi’s lead candidates, CLD-101 and CLD-201, target significant market opportunities estimated between $13 billion and $15 billion in the U.S. OS Therapies CEO Paul Romness will highlight OST-HER2, an immunotherapy targeting HER2-positive osteosarcoma and solid tumors, with potential for accelerated FDA approval. The company also advances a…

Site Search

Company Search

Tag: Calidi Biotherapeutics Inc. CLDI